Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months.

CONCLUSION: The novel, low-dose copper and nitinol IUD demonstrated high efficacy and safety in this phase 2 U.S. Food and Drug Administration trial and warrants further expanded study in a phase 3 clinical trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02446821. FUNDING SOURCE: Sebela Pharmaceuticals, Inc. PMID: 32168217 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32168217?dopt=Abstract

Source: Obstetrics and Gynecology - March 9, 2020 Category: OBGYN Authors: Turok DK, Nelson AL, Dart C, Schreiber CA, Peters K, Schreifels MJ, Katz B Tags: Obstet Gynecol Source Type: research